Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | BMC Cancer

Figure 3

From: A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer

Figure 3

Unadjusted, unstratified OS for the maintenance phase (from randomization) for the Q-ITT analysis population. Pemetrexed + BSC: OS median time = 12.2 months (95% CI = 5.6-20.6). BSC: OS median time = 11.8 months (95% CI = 6.3-25.6) one-sided p-value = 0.3619.

Back to article page